<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the dynamics of non-invasive electrophysiologic (<z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, HRV, HRT, mTWA) and humoral (red blood cells ω-3 index) SCD predictors at the background of therapy with ω-3 PUFA in patients with iscemic <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Materials and METHODS: The study included 80 patients </plain></SENT>
<SENT sid="2" pm="."><plain>Inclusion criteria were: documented <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> (history of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, stable <z:mp ids='MP_0006112'>angina</z:mp>, previous surgical intervention on coronary arteries (coronary artery bypass grafting [CABG], percutaneous coronary intervention [PCI]), positive stress tests, signs of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> in coronary angiography or computer tomography of coronary arteries; <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, according to registered Holter monitoring (<z:mp ids='MP_0010018'>PVCs</z:mp> in the number of 250 or more per day and /or intermittent <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> paroxysms); continuous antiarrhytmic therapy for at least 1 month before inclusion (ω-blockers and /or <z:chebi fb="0" ids="2663">amiodarone</z:chebi>), 4) informed consent to participate in the study </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> criteria for a good anti-arrhythmic effect (reducing the number of <z:mp ids='MP_0010018'>PVCs</z:mp> by 75% and more, paired <z:mp ids='MP_0010018'>PVCs</z:mp> by 90% or more, the complete elimination of unstable <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> paroxysms) after 3 months of therapy were observed in 16% of patients, and 6 months after - in 46% </plain></SENT>
<SENT sid="4" pm="."><plain>A small but significant increase in the number of <z:mp ids='MP_0010018'>PVCs</z:mp>, paired <z:mp ids='MP_0010018'>PVCs</z:mp> and <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> paroxysms was noted in the control group </plain></SENT>
<SENT sid="5" pm="."><plain>As a result, after 6 months of observation the mean SDNN in patients taking ω-3 PUFA, significantly exceeded the value of the one in the control group </plain></SENT>
<SENT sid="6" pm="."><plain>Six months after, the mean value of TO was significantly lower and the mean value of TS - higher than in the control group </plain></SENT>
<SENT sid="7" pm="."><plain>After 6 months of therapy with ω-3 PUFA it a significant increase of red blood cells ω-3 index was show by increasing the value of both <z:chebi fb="113" ids="28364">EPA</z:chebi> (an average of 78%) and DHA (an average of 42 %) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: 6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired <z:mp ids='MP_0010018'>PVCs</z:mp>, the number of unstable <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> paroxysms, improves HRT, HRV, increases red blood cells ω-3 index </plain></SENT>
<SENT sid="9" pm="."><plain>The long-term (more than 3 months) ω-3 PUFA supplementation must consider be taken into in mTWA assessment to avoid false-positive findings in the SCD risk stratification </plain></SENT>
</text></document>